Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation [11]

Nephrology Dialysis Transplantation

Volumn 22, Issue 6, 2007, Pages 1791-1792

  Thierry, Antoine ^a   Dreyfus, Brigitte ^a   Bridoux, Frank ^a   Ayache, Ramzi Abou ^a   Milin, Serge ^a   Guilhot, François ^a   Touchard, Guy ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AZATHIOPRINE; BCR ABL PROTEIN; CYCLOSPORIN A; IMATINIB; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; STEROID; THYMOCYTE ANTIBODY;

ADULT; BREAST CANCER; CANCER HORMONE THERAPY; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC DIARRHEA; CHRONIC MYELOID LEUKEMIA; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; LONG TERM CARE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS;

EID: 34447556019     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm052     Document Type: Letter

References (6)

1. Adler KR, Lempert N, Scharfman WB. Chronic granulocytic leukemia following successful renal transplantation. Cancer 1978; 41: 2206-2208
2. Koca E, Cetiner D, Goker H et al. Complete cytogenetic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation. Clin Nephrol 2005, 64: 324-325
3. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med 2005; 352: 1049-1050
4. Gottari M, Manzato E, Gherlinzoni F. Imatinib and hyperlipemia. N Engl J Med 2005; 353: 2722-2723
5. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75: 1147-1153
6. Sihvola R, Tikkanen J, Krebs R et al. Platelet-derivated growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation 2003; 75: 334-339